January 30, 2013
1:00 pm – 2:00 pm EST

Sponsored by:

Symposium Course Description:

Drug discovery requires years of hard work and expertise. Most drug discoverers do not go at this task alone these days. Partnership with ChanTest from target validation to pre-clinical GLP safety testing (and anywhere in between) can shorten the time to market and provide the confidence going into clinical trials that comes from the highest quality data and customer support in the business.

Learning Objective Bullet Points:

• The Drug Discovery process from A-Z
• Admitting you need help is the first step to recovery
• The latest in automated patch clamp for ion channel assays
• ChanTest products and services make drug discoverers successful

Who Should Attend:
CEO’s, VP’s of Research, Safety Heads, Group leaders, Drug Discoverers

Program Agenda:

1:00 pm – Welcome and background information
1:05 pm – Presentation by Chris Mathes (ChanTest)
1:40 pm – Prentation by Simon Hirst (Sygnature)
2:00 pm – End

Presentation Information:

ChanTest: Drug Discovery PartnerChris Mathes, Ph.D.
Chief Commercial Officer
ChanTest Corporation
14656 Neo Parkway
Cleveland, Ohio 44128
732-586-1073
cmathes@chantest.com
www.chantest.com
Twitter: @ChanTest

"Federated" CRO Model, Intelligent Integrated Drug DiscoverySimon Hirst, Ph.D.
CEO
Sygnature Discovery
BioCity
Pennyfoot Street
Nottingham, NG1 1GF
UK
s.hirst@sygnaturediscovery.com
+44-115 941 5401

Moderator:Glenn Kirsch, Ph.D.
Senior Director, Pharmacology and Program Management
ChanTest Corp.
gkirsch@chantest.com

Speaker Information:

Chris Mathes, Ph.D., M.B.A. is the Chief Commercial Officer (CCO) since September 2012 and over sees sales, marketing and customer relations at ChanTest. Previously, Dr. Mathes was involved in the development, testing and marketing of novel high-throughput electrophysiology systems. Overall, Dr. Mathes has more than 20 years of experience with the patch clamp technique and ion channel research. Mathes earned a B.S. in Biology (with departmental honors) from Stanford University. He received his Ph.D. degree in Neuroscience from the University of California, Los Angeles. More recently, Mathes earned an Executive M.B.A. degree from Rutgers University (Beta Gamma Sigma).

Simon Hirst, Ph.D. is Sygnature’s Founder and has been Chief Executive Officer since 2004. He is a medicinal chemist with 21 years experience in the pharmaceutical industry. Simon has been engaged in the full spectrum of drug discovery programmes - from lead generation libraries, hit-to-lead campaigns, all the way to successful lead optimisation projects and candidate drug selection. He has broad-ranging experience of research in a large pharmaceutical company (AstraZeneca), a mid-size biotech (OSI Pharmaceuticals); as well as in a more commercial environment at CombiPure Ltd., where he was Managing Director and Director of Chemistry. Simon has a BSc (Hons.) in chemistry, and a PhD in synthetic organic chemistry from the University of Nottingham, and undertook post-doctoral research at the University of Pittsburgh